Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies-Reference-Cited by-同舟云学术

Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies

Published:2023-01 Issue:1 Volume:18 Page:9-24
ISSN:1776-2596
Container-title:Targeted Oncology
language:en
Short-container-title:Targ Oncol

Author:

Popat Sanjay^ORCID,Ahn Myung-Ju,Ekman Simon,Leighl Natasha B.,Ramalingam Suresh S.,Reungwetwattana Thanyanan,Siva Shankar,Tsuboi Masahiro,Wu Yi-Long,Yang James Chih-Hsin

Funder

AstraZeneca

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s11523-022-00941-7.pdf

Reference89 articles.

1. Mizuno T, Konno H, Nagata T, et al. Osteogenic and brain metastases after non-small cell lung cancer resection. Int J Clin Oncol. 2021;26(10):1840–6.

2. Kenmotsu H, Yamamoto N, Yamanaka T, et al. Randomized phase III study of pemetrexed plus cisplatin versus vinorelbine plus cisplatin for completely resected stage II to IIIA nonsquamous non-small-cell lung cancer. J Clin Oncol. 2020;38(19):2187–96.

3. Cagney DN, Martin AM, Catalano PJ, et al. Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study. Neuro Oncol. 2017;19(11):1511–21.